Upon completion of the video presentation, to finish the activity and claim your credit, please click here
Supported by an educational grant from Puma Biotechnology.
Advances in Extended Adjuvant HER2-Positive Early Breast Cancer
G. Thomas Budd, MD
Taussig Cancer Center at Cleveland Clinic
Wendy H. Vogel, MSN. FNP, AOCNP®
Wellmont Cancer Institute
Examine the mechanisms of action of extended adjuvant therapies for HER2-positive early breast cancer, in addition to strategies for combating patients’ side effects and the latest guidelines on HER2 testing. Advanced practitioners can also learn about their critical role in properly selecting patients for treatment, educating them about their treatment options, and managing treatment adherence.
These CME/CE/CPE accredited activities are jointly provided by